162 related articles for article (PubMed ID: 27672337)
1. Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD.
Ramos M; Haughney J; Henry N; Lindner L; Lamotte M
Clinicoecon Outcomes Res; 2016; 8():445-56. PubMed ID: 27672337
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.
de Nigris E; Treharne C; Brighton N; Holmgren U; Walker A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2022; 17():2987-3000. PubMed ID: 36444374
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.
Capel M; Mareque M; Álvarez CJ; Lindner L; Oyagüez I
Clin Drug Investig; 2018 Jul; 38(7):611-620. PubMed ID: 29654555
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain.
Trigueros JA; Garin N; Baloira A; Aceituno S; Calvo A; Prades M; Touron C; Martínez A; Torres C
Int J Chron Obstruct Pulmon Dis; 2022; 17():2905-2917. PubMed ID: 36411773
[TBL] [Abstract][Full Text] [Related]
5. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update.
D'Urzo AD; Singh D; Donohue JF; Chapman KR; Wise RA
Expert Rev Respir Med; 2021 Sep; 15(9):1093-1106. PubMed ID: 34137664
[No Abstract] [Full Text] [Related]
6. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
7. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.
Karabis A; Mocarski M; Eijgelshoven I; Bergman G
Clinicoecon Outcomes Res; 2014; 6():175-85. PubMed ID: 24741321
[TBL] [Abstract][Full Text] [Related]
9. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.
D'Urzo AD; Singh D; Donohue JF; Chapman KR
Ther Adv Respir Dis; 2019; 13():1753466619850725. PubMed ID: 31096854
[TBL] [Abstract][Full Text] [Related]
10. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD.
Tebboth A; Ternouth A; Gonzalez-Rojas N
Clinicoecon Outcomes Res; 2016; 8():667-674. PubMed ID: 27853383
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
Medic G; Lindner L; van der Weijden M; Karabis A
Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
[TBL] [Abstract][Full Text] [Related]
12. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model.
Liu J; He X; Wu J
Appl Health Econ Health Policy; 2022 Sep; 20(5):743-755. PubMed ID: 35478081
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
[TBL] [Abstract][Full Text] [Related]
15. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P; Matera MG
Expert Opin Pharmacother; 2013 Apr; 14(6):775-81. PubMed ID: 23472632
[TBL] [Abstract][Full Text] [Related]
16. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
Hogan TJ; Geddes R; Gonzalez ER
Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
[TBL] [Abstract][Full Text] [Related]
17. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.
Singh D; D'Urzo AD; Donohue JF; Kerwin EM; Molins E; Chuecos F; Ribera A; Jarreta D
Int J Chron Obstruct Pulmon Dis; 2019; 14():2835-2848. PubMed ID: 31827323
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
19. Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease.
Lal C; Strange C
Expert Opin Pharmacother; 2015 Feb; 16(3):427-34. PubMed ID: 25597386
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi.
Cazzola M; Calzetta L; Page CP; Rogliani P; Facciolo F; Gavaldà A; Matera MG
Eur J Pharmacol; 2014 Dec; 745():135-43. PubMed ID: 25446566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
